Circulating chemokine levels and receptor polymorphisms have potential as biomarkers for fibrosis stages in patients with chronic hepatitis C infection
- 18 January 2025
- journal article
- research article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-12
Abstract
Background Chemokines and their receptors, which regulate lymphoid organ development and immune cell trafficking, are integral to the mechanisms underlying viral control, hepatic inflammation, and liver damage in chronic hepatitis C (CHC) infection. This study explores the potential relationship between serum chemokine levels/polymorphisms and hepatitis C infection in affected individuals, with a particular focus on their utility as biomarkers across different stages of fibrosis. Methods and results Serum levels of the chemokines CXCL11, CXCL12, and CXCL16 were measured in patients with mild/moderate and advanced fibrosis due to CHC, as well as in healthy controls, using the ELISA method. The CXCL12 rs1801157 and CXCL16 rs2277680 polymorphisms were analyzed in blood samples from patients and healthy controls through RT-qPCR. Serum levels of CXCL11, CXCL12, and CXCL16 were significantly elevated in patients with advanced fibrosis compared to healthy controls. Furthermore, CXCL11 levels were markedly higher in patients with advanced fibrosis than in those with mild/moderate fibrosis. The frequency of the CXCL12 rs1801157 AA genotype was significantly higher in the advanced fibrosis group compared to the healthy control group. Similarly, the CXCL16 rs2277680 GA genotype was significantly more prevalent in the advanced fibrosis group than in the mild/moderate fibrosis group. Conclusions The current study highlights that, in addition to the potential association between chemokine levels/polymorphisms and an increased risk of disease complications and pathological progression in CHC infection, serum CXCL11 levels and the CXCL16 rs2277680 allel polymorphism may be important factors in determining the fibrosis stage of hepatitis C infection.Keywords
Funding Information
- Mersin University Scientific Research Projects ([2021-1-TP2-4131])
- Mersin University Scientific Research Projects ([2021-1-TP2-4131])
This publication has 37 references indexed in Scilit:
- Global mortality of chronic liver diseases attributable to Hepatitis B virus and Hepatitis C virus infections from 1990 to 2019 and projections to 2030.Journal of Infection and Public Health, 2024
- Hepatitis CThe Lancet, 2023
- Circulating levels of CXCL11 and CXCL12 are biomarkers of cirrhosis in patients with chronic hepatitis C infectionCytokine, 2019
- Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus–Related Acute Liver FailureCellular and Molecular Gastroenterology and Hepatology, 2019
- Serum CXCL10, CXCL11, CXCL12, and CXCL14 chemokine patterns in patients with acute liver injuryCytokine, 2018
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapyCancer Treatment Reviews, 2018
- Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C‐X‐C chemokine receptor 4 axisHepatology, 2015
- Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2Clinical Rheumatology, 2013
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis†Hepatology, 1981